Post-earnings recap
Reported
Tue, May 5, 2026
EPS actual
$0.52
EPS est.
$0.23
EPS surprise
+126.09%
1-day move
-1.43%
Veracyte's strong EPS performance significantly exceeded expectations, indicating better-than-expected profitability. However, the stock fell by 1.43%, suggesting that investors may have been disappointed by the lack of revenue data and guidance. The absence of management commentary also leaves uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.52 | $0.33 | +126.09% |
| Revenue | — | $130M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Veracyte, Inc. is a biotechnology company focused on improving patient outcomes through innovative genomic diagnostics. Operating in the health care sector, Veracyte's tests help physicians make more informed decisions, particularly in cancer diagnosis and treatment, which is increasingly important in today's health landscape.
Last quarter
In the last quarter, Veracyte reported an EPS of $0.53, significantly exceeding expectations. The stock reacted positively, gaining 0.08% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+241.19%
Avg 1-day reaction
+0.51%
Analysts are generally optimistic about Veracyte's upcoming earnings, expecting solid performance based on historical trends.
Bull case
If Veracyte meets or exceeds the EPS and revenue estimates, it could reinforce investor confidence and lead to a positive stock reaction.
Bear case
However, if the company fails to meet expectations, particularly after a series of strong earnings surprises, it could lead to a significant sell-off.
Key metrics to watch
EPS
$0.33Earnings per share (EPS) is a key indicator of the company's profitability and is closely watched by investors.
Revenue
$130MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Veracyte's EPS exceed the consensus estimate of $0.33?
Given the company's strong history of earnings surprises, a beat could significantly boost investor sentiment.
Q2
What revenue growth can Veracyte report against the consensus of $130M?
Revenue performance is crucial for understanding market demand and the effectiveness of their product offerings.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The Street may be underestimating Veracyte's ability to leverage recent product innovations, which could drive higher-than-expected revenue growth.
Supporting evidence
Veracyte has consistently exceeded EPS estimates, suggesting strong operational execution.
The options market indicates heightened volatility, which may reflect investor anticipation of a significant announcement or update.
Recent insider activity, while routine, could suggest confidence in upcoming performance.
Key risk
If revenue growth exceeds $135M, it could challenge current market expectations and lead to a reevaluation of the stock's potential.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it will either reinforce the company's growth trajectory or raise concerns about its market position.
Bull confirmed if
An EPS of $0.37 or higher would confirm strong operational performance and investor confidence.
Bear confirmed if
An EPS below $0.23 would signal potential issues with market demand or operational challenges.
What the market is pricing for the move.
Implied Move
±18.46%
Historical Avg
±2.1%
The options market is pricing in a larger-than-average move, indicating that investors expect significant volatility around the earnings report.
Options are pricing ±18.5% while VCYT has averaged ±2.1% over the last 8 prints — setup is pricing rich.
ATM IV
1.4%
30d HV
50.0%
Smart-money positioning from the most recent 13F filings.
Institutional
114.78%
of float
Insider
0.49%
of float
Holders
515
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
13,486,437 sh · $582.1M
16.78%
2.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Veracyte beats expectations, history suggests a potential stock increase of around +0.33%, confirming strong operational momentum.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a stock decline, with historical patterns indicating a possible drop of around -4.16%.
The lines on the call that would change the story.
FMR, LLC
7,702,746 sh · $332.5M
9.58%
-0.8%
Artisan Partners Limited Partnership
5,538,404 sh · $239.0M
6.89%
0.8%
Vanguard Portfolio Management LLC
4,716,191 sh · $203.6M
5.87%
6.1%
State Street Corporation
4,698,128 sh · $202.8M
5.84%
-6.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.